Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.59% | 37.41% | 31.21% | 11.89% | -1.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.59% | 37.41% | 31.21% | 11.89% | -1.79% |
| Cost of Revenue | 28.21% | 32.32% | 24.10% | 13.54% | -3.77% |
| Gross Profit | 43.66% | 40.66% | 35.68% | 10.82% | -0.46% |
| SG&A Expenses | 10.00% | -18.21% | 12.40% | -5.07% | -15.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.34% | 3.04% | 16.16% | 1.57% | -6.69% |
| Operating Income | 752.80% | 4,332.74% | 239.67% | 88.95% | 62.86% |
| Income Before Tax | 1,163.21% | 6,464.91% | 295.83% | 99.32% | 74.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,129.07% | 6,197.37% | 295.83% | 99.32% | 74.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,129.07% | 6,197.37% | 295.83% | 99.32% | 74.13% |
| EBIT | 752.80% | 4,332.74% | 239.67% | 88.95% | 62.86% |
| EBITDA | 1,064.47% | 15,108.33% | 306.17% | 97.60% | 69.69% |
| EPS Basic | 1,101.54% | 6,120.00% | 292.97% | 99.32% | 74.41% |
| Normalized Basic EPS | 1,124.39% | 6,655.56% | 292.50% | 99.45% | 74.21% |
| EPS Diluted | 700.00% | -- | 256.25% | 99.33% | 60.63% |
| Normalized Diluted EPS | 1,058.54% | 6,266.67% | 288.75% | 99.45% | 74.21% |
| Average Basic Shares Outstanding | 3.43% | 2.43% | 1.23% | 0.79% | 0.58% |
| Average Diluted Shares Outstanding | 10.64% | 8.71% | 3.62% | 0.79% | 0.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |